A bdominal aortic aneurysm (AAA) is a pathological dilatation of the aorta that can result in rupture and death. It is a common disease among older people. A national screening program for 65-year-old men is being introduced in the United Kingdom, with the aim of reducing mortality from ruptured AAA by offering surgery to those with large aneurysms.
AAA shares many features with other cardiovascular diseases. Lifestyle risk factors include tobacco use 1,2 and inactivity. 3 Coronary artery disease, cerebral vascular disease, and peripheral vascular disease are found at higher rates among people with AAA, suggesting that there are shared exposures or shared disease pathways. 1, [4] [5] [6] AAA exhibits significant heritability and is observed to cluster in families. 7 A family history of AAA confers a risk of disease that is comparable in effect size with cigarette smoking. 4, 5 The role of cholesterol and atherosclerosis in AAA is not well understood. Atherosclerosis often accompanies AAA, but whether the association is causative is controversial. 8 Higher levels of high-density lipoprotein-cholesterol are associated with protection against AAA, 9, 10 and raised serum total cholesterol is associated with increased risk. 3, 4 The effect of serum low-density lipoprotein (LDL) remains unclear, with some reports of increased risk but inconclusive meta-analyses. [9] [10] [11] [12] Genetic polymorphisms of LRP1 13 , DAB2IP, 14 and SORT1 15 were discovered to be associated with susceptibility to AAA in genome-wide association studies. CDKN2B-AS [16] [17] [18] and IL6R 19 were identified and confirmed with a high level of certainty in candidate-gene studies. Relatively few genetic risk factors for AAA have been identified to date, which is unexpected considering its heritability, complex pathogenesis, and similarity to other cardiovascular diseases for which many risk associations have been found. We reanalyzed our genome-wide association study with particular emphasis on limiting possible sources of experimental method-related false associations and carried through to replication newly identified putative associations at a lower threshold of discovery association.
Materials and Methods

Study Design and Participants
All participating centers had approval from appropriate local research ethics committees to conduct their studies, and all participants gave written informed consent. Identifiable information was not provided to collaborating researchers. The study adheres to the tenets of the Declaration of Helsinki. The study design has been described previously. 13 A case-control genome-wide association study was carried out using 1830 cases from the United Kingdom, New Zealand, and Australia who had an infrarenal aorta diameter of ≥30 mm on transabdominal ultrasound scan or a ruptured AAA and 5435 unscreened population controls from the 1958 Birth Cohort and National Blood Service cohort from the Wellcome Trust Case Control Consortium. The mean age of the cases was 73 years, and the median infrarenal aortic diameter was 4.6 cm. Median age of the Blood Transfusion Service cohort was 45 years, and participants from the 1958 Birth Cohort were aged 52 years at the time of genotyping. Associations with genomic inflation-corrected P<5×10 −8 in additive model logistic regression were considered to be significant at a genome-wide level, and P values <1×10 −4 were considered to be suggestive of an association. The threshold of P<10 −4 was chosen to be an order of magnitude greater than the original analysis to investigate putative associations that might be apparent after stringent quality control aimed at excluding artifactual false associations. A 2-stage replication study was conducted. First, a representative single-nucleotide polymorphism (SNP) from each associated locus was carried through to an in silico replication study that comprised 452 cases and 27 712 controls from Iceland and 840 cases and 2791 controls from The Netherlands. Associations from known loci at CDKN2B-AS1, LRP1, and IL6R, and the previously investigated GPC6, were excluded from further analyses. SNPs were chosen for predicted compatibility with a Sequenom multiplex reaction. SNPs that showed significant association at P<0.05 after Bonferroni correction for multiple testing in stage 1 were carried through to a laboratory replication study of 706 cases and 1063 controls from the United Kingdom (Belfast, Leeds, and Leicester) and 507 cases and 199 controls from Viborg, Denmark. The same diagnostic criteria were used for cases in the replication studies as in the discovery study. Statistical significance at stage 2 also had P<0.05 after Bonferroni correction for multiple testing. Finally, to confirm any positive findings from stage 2, we used in silico data from a recent genome-wide association study of AAA. 15 This New Zealand study consisted of 885 additional cases of AAA and 1000 additional controls, none of which was included in the original genome-wide study.
Discovery Study Microarray Experiment and Genotyping
Cases were genotyped at the Wellcome Trust Sanger Institute using the Illumina Human670 Quad Custom version 1 bead chip, and the WTCCC2 common controls were genotyped using the Illumina 1.2M Duo Custom version 1a bead chip. The raw idat data produced at the Sanger Institute were normalized and genotyped using the corrected robust linear mixture model crlmm package 20 in R version 2.14.0 on the Queen's University Belfast High-Performance Computing Dell Cluster using SOCK parallelization in 4 batches of ≈1900 individuals. Quality control steps are described in the onlineonly Data Supplement.
Discovery Study Association Analysis
The genome-wide study was analyzed using an additive model which assumes that each extra copy of an allele contributes the same change in odds and that 2 copies of an allele confer twice the odds of 1 copy. The ancestry of participants was analyzed by principal components analysis (Methods in the online-only Data Supplement). The association analysis was conducted using logistic regression with ancestry eigenvectors included as covariates for the 5 statistically significant axes to correct the analysis for residual population stratification. The analysis was performed using PLINK version 1.07.
Replication Stage Genotyping and Analysis
A Sequenom iPLEX was designed using MySequenom software and conducted according to the manufacturer's protocols. Primer sequences are shown in Table III in the online-only Data Supplement. Briefly, a multiplex polymerase chain reaction was conducted on an ABI 9700 Dual 384-well thermal cycler, unincorporated dNTPs were neutralized using a shrimp alkaline phosphatase reaction, primer extension was conducted using the iPLEX termination mix and further cycling, and conditioning resin was added before nanodispensing and measurement of extension product on a Sequenom MassArray. Cluster plots were inspected using Typer 4.0 Software. In silico analyses were provided from Icelandic (452 cases and 27 712 controls) and Dutch (840 cases and 2791 controls) AAA genome-wide association studies. Association P values from the Icelandic analyses were adjusted for population relatedness and potential population stratification by the genomic control factor (λ=1.143). The Dutch study did not require correction (λ=1) 14 and was, therefore, used without correction in our study. LDL receptor (LDLR) rs6511720 was genotyped as part of a Sequenom iPLEX in a UK replication group (729 cases and 1104 controls) and a replication group from Viborg, Denmark (496 cases and 176 controls). Twelve UK cases, 25 UK controls, 6 Viborg cases, and 4 Viborg controls were excluded because of low genotyping rate (<90%). The remaining genotyping rate was 99.9%.
The association analyses were conducted using additive model logistic regression in PLINK for the laboratory study with no covariates. Data from the Iceland and Netherlands studies were analyzed in NEMO. 21 The additional New Zealand genome-wide study (885 cases and 1000 controls) was conducted using the Affymetrix SNP6 GeneChip array and tested for association between AAA and LDLR rs6511720 using additive model logistic regression in PLINK. Full details of this study have been described previously. 15 Logistic regression analyses with adjustment for age (United Kingdom, Denmark, and New Zealand replication studies) and LDL-cholesterol (adjusted for statin use; New Zealand) were also conducted.
Meta-analysis
The results from the individual studies were combined using inverse variance-weighted meta-analysis in METASOFT. Between-study heterogeneity was investigated by estimating the heterogeneity index (I 2 ) also in METASOFT. Fixed-effects and Han Eskin random-effects meta-analyses were conducted. In the absence of heterogeneity, a fixed-effects model was used, and in its presence, Han Eskin random-effects model was used. 22 Han Eskin meta-analysis is a form of random-effects meta-analysis for the use in genetic studies in the presence of heterogeneity.
Imputation
Targeted imputation of LDLR was carried out using IMPUTE2 23 with reference to all populations in The 1000 Genomes Project Phase 1 integrated version 3 data release. Thirty Markov chain Monte Carlo iterations, including a burn in of 10 iterations and 40 conditioning states, were used. Population size (-Ne) was set to 20 000. Imputed regions were each 2 Mb in size. Visualization was performed using Locus Zoom.
Results
In the final discovery study, 1755 cases (1554 men and 201 women) and 5314 controls (2706 men and 2608 women) were genotyped for 503 892 SNPs that passed all quality control thresholds. The final genotyping rate was 99.85%. A quantilequantile plot is shown in Figure II in the online-only Data Supplement.
No SNPs had association P values reaching genome-wide significance level in the discovery study. Twenty-three SNPs in 12 loci had suggestive association P values of <1×10 −4 ( Figure 1 ; Table II in the online-only Data Supplement). Eight SNPs were carried through to in silico replication, one of which remained significant after Bonferroni correction for multiple testing (LDLR rs6511720 A; odds ratio [OR], 0.79 [0.69-0.89]; P=2.34×10 −4 ; Figure 2 ). The same allele was associated significantly in an independent laboratory replication (OR, 0.73 [0.57-0.94]; P=0.016; Table) . Han Eskin random-effects meta-analysis of combined replication stages 1 and 2 produced an OR of 0.78 (0.69-0.87; P=1.95×10 −5 ) for rs6511720 A, and both the discovery and the replication steps give an OR of 0.78 (0.72-0.85), an association that reached genome-wide significance (P=6.97×10 −9 ).
The additional New Zealand genome-wide study data set provided further independent replication of the association (OR, 0.68 [0.50-0.93]; P=4.8×10 −3 ). The combination of the New Zealand results with the rest of the study by Han Eskin random-effects meta-analysis resulted in an OR of 0.76 (0.70-0.83; P=2.08×10 −10 
Discussion
We report that rs6511720 in LDLR is a novel genetic risk factor for AAA. The effect associated with this SNP is similar to that reported for LRP1, DAB2IP, IL6R, and SORT1. LDLR is the simplest of a family of LDL-cholesterol cell surface receptors 24 that also includes the AAA-associated LRP1. 13 LDLR rs6511720 is one of the most important LDLcholesterol-associated variants in genome-wide studies of lipid traits. [25] [26] [27] [28] [29] [30] [31] Importantly, a relationship between AAA and LDL-cholesterol levels is not presently established. The most complete meta-analysis of the relationship was inconclusive, and individual reports are inconsistent. 9, [32] [33] [34] Our report of association between LDLR polymorphism and AAA susceptibility suggests that either LDL-cholesterol is important in AAA pathogenesis or LDLR polymorphism has an effect on another causal pathway. The adjusted results of the New Zealand study suggest that the association is independent of LDL-cholesterol levels.
Despite this uncertainty, our finding is consistent with other knowledge of AAA pathogenesis. LDLR-knockout (Ldl−/−) mice are used as disease models for AAA. 35 The same LDLR allele (rs6511720 A) that we report is associated with protection against AAA is also associated with protection against coronary artery 25, 28, 29, 36, 37 and carotid artery atherosclerotic plaque formation. 38 A recent meta-analysis of the use of lipidlowering therapy in AAA to reduce the rate of expansion has shown some benefit. This finding is consistent with LDLcholesterol having a direct role in AAA pathogenesis. 34 We are aware of the limitations of this study. The strict quality control measures used in this analysis allowed us to identify the LDLR locus by excluding false-positive associations. We accepted the possibility of also excluding some true associations as a consequence. Meta-analysis of genome-wide association studies for AAA may offer a future opportunity to identify further AAA loci that have been excluded. The rs6511720 SNP was associated with AAA at a similar level in the original study analysis, as were many additional likely spurious associations. Although the LDLR locus could have been identified in the original discovery analysis at P<10 −4 , Bonferroni correction for the attempted replication of many additional putative associations would have vastly reduced the power to replicate true associations. The ORs in the Denmark and New Zealand studies were unaffected by adjustment for age, and the association remained significant after inclusion of age as a covariate in a logistic regression model. The UK replication study that showed no association with rs6511720 was unaffected by the inclusion of age in the logistic regression.
The use of the standard 3-cm definition of AAA has limitations as a phenotype for genetic studies because it is arbitrary, and risk of AAA by this measure is affected by height and sex. Future studies might benefit from using a definition of AAA that incorporates an individual's stature. Alternatively, longitudinal studies of disease progression have the potential to be useful, although different gene associations might be found to affect progression. Future studies to determine whether LDL-cholesterol levels are causal in the pathogenesis of AAA could use Mendelian randomization that would require prospective standardized collection of data for serum lipids and the use of lipid-lowering therapies. We do not have sufficient extra information to explore heterogeneity in the rs6511720 association. Possible causes for differences in the effect size between the components of the study include chance and gene-environment interactions because of differences in exposures (tobacco or lipid-lowering therapy) whose prevalence differs over time or between places and case-mix variation (whereby screening-detected AAA, elective surgical cases, and ruptured AAA are differently represented betweenstudy components). Two of the 6 component studies in this investigation did not show a significant association between rs6511720 A and AAA. This is similar to the situation in the 3 other published genome-wide studies of AAA. [13] [14] [15] Possible reasons for this include low power in individual component studies, type II error, and the winner's curse. 39 Our study made use of the Wellcome Trust Case Control Consortium shared, unscreened controls. The use of population controls offers the advantages of reduced testing for participants, shared costs between projects, and increased power because of the ready availability of participants. A potential drawback is a reduced effect size caused by the presence of a small number of people who would meet the case definition within the control group and the increased risk of type II errors. 40 Our finding that LDLR polymorphism affects odds of AAA suggests that study of relationships between LDL-cholesterol homeostasis and AAA pathogenesis may be productive in identifying therapeutic and preventative strategies.
